In 2008, Boehringer Ingelheim posted net sales of 11.6 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development.
For more information please visit http://www.boehringer-ingelheim.com
---------------------------------
[1] An anti-angiogenic agent inhibits angiogenesis, the process of formation of vessels toward the tumour. The vessel supplies the tumour with oxygen and nutrients to enable its further growth, a pre-requisite for the tumour to spread.
[2] Ledermann J, et al. J Clin Oncol 2009; 27 (Suppl 15): Abstract 5501
[3] P Boyle and B Levin (eds). "World Cancer Report 2008.", World Health Organization: International Agency for Research on Cancer. Lyon: 2008
[4] American Cancer Society. "Ovarian Cancer Detailed Guide." Atlanta: 2008. Available at: http://documents.cancer.org/114.00/114.0.... Accessed on 5 May 2009.
Corporate / Global Media Contact, Julia Meyer-Kleinmann, Head Science & Technology, Communications, Boehringer Ingelheim GmbH, Tel: +49-6132-77-8271, Email: press@boehringer-ingelheim.com